National guidelines for the control and prevention of methicillin-resistant Staphylococcus aureus--what do they tell us?

Guidelines to control and prevent methicillin-resistant Staphylococcus aureus (MRSA) infection are available in many countries. Infection control and prevention teams determine local strategies using such national guidelines, but not all guidelines involve a rigorous assessment of the literature to determine the strength of the recommendations. Available guidelines drafted by national agencies or prominent professional organisations in Germany, New Zealand, North America, The Netherlands, Ireland and the UK were reviewed. Significant literature reviews were a component of guidelines from the UK and North America. Recommendations were not graded on the strength of the evidence in guidelines from New Zealand and The Netherlands. The Netherlands, a country with a very low prevalence of MRSA, had the simplest set of guidelines. Few of the recommendations in any of the guidelines achieved the highest grading, i.e., based on well-designed, experimental, clinical or epidemiological studies, even though the logic of the proposed measures is clear. The onset of community-acquired MRSA is reflected in the recent publication of guidelines from North America. New developments, such as rapid testing and mathematical modelling, are of importance in helping to control MRSA in settings of both low and high endemicity. National guidelines are increasingly evidence-based, although good scientific studies concerning some aspects of MRSA control are lacking. However, general principles, e.g., early detection and isolation, are recommended by all guidelines. There is still a role for consensus and the opinion of experts in devising national guidelines.

[1]  R. Cunningham,et al.  Effect on MRSA transmission of rapid PCR testing of patients admitted to critical care. , 2007, The Journal of hospital infection.

[2]  H. Loveday,et al.  A systematic review of the evidence for interventions for the prevention and control of meticillin-resistant Staphylococcus aureus (1996-2004): report to the Joint MRSA Working Party (Subgroup A). , 2006, The Journal of hospital infection.

[3]  H. Humphreys,et al.  Guidelines for the control and prevention of meticillin-resistant Staphylococcus aureus (MRSA) in healthcare facilities. , 2006, The Journal of hospital infection.

[4]  O. Diekmann,et al.  Controlling methicillin-resistant Staphylococcus aureus: quantifying the effects of interventions and rapid diagnostic testing. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[5]  Stephan Harbarth,et al.  Evaluation of rapid screening and pre-emptive contact isolation for detecting and controlling methicillin-resistant Staphylococcus aureus in critical care: an interventional cohort study , 2006, Critical care.

[6]  H. Humphreys Implementing guidelines for the control and prevention of methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: how valid are international comparisons of success? , 2006, The Journal of hospital infection.

[7]  R. Gaynes,et al.  Changes in the epidemiology of methicillin-resistant Staphylococcus aureus in intensive care units in US hospitals, 1992-2003. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  J. Weese,et al.  Guidelines for the prevention and management of community-associated methicillin-resistant Staphylococcus aureus: A perspective for Canadian health care practitioners. , 2006, The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale.

[9]  Lynne Dailey,et al.  Methicillin-resistant Staphylococcus aureus, Western Australia , 2005, Emerging infectious diseases.

[10]  T. Lodise,et al.  Clinical and economic impact of methicillin resistance in patients with Staphylococcus aureus bacteremia. , 2005, Diagnostic microbiology and infectious disease.

[11]  S. Swidsinski,et al.  Cost analysis of a hospital-wide selective screening programme for methicillin-resistant Staphylococcus aureus (MRSA) carriers in the context of diagnosis related groups (DRG) payment. , 2005, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[12]  W. Huskins,et al.  Controlling meticillin-resistant Staphylococcus aureus, aka “Superbug” , 2005, The Lancet.

[13]  Steve Shaw,et al.  Isolation of patients in single rooms or cohorts to reduce spread of MRSA in intensive-care units: prospective two centre study , 2005, The Lancet.

[14]  A. Voss,et al.  Methicillin-ResistantStaphylococcus aureus in Europe , 2005, European Journal of Clinical Microbiology and Infectious Diseases.

[15]  O. Lyytikäinen,et al.  Changing epidemiology of methicillin-resistant Staphylococcus aureus in Finland. , 2004, The Journal of hospital infection.

[16]  Outi Lyytikäinen,et al.  Methicillin-resistant Staphylococcus aureus in Europe, 1999–2002 , 2004, Emerging infectious diseases.

[17]  B. Cooper,et al.  Methicillin-resistant Staphylococcus aureus in hospitals and the community: stealth dynamics and control catastrophes. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[18]  H. Wertheim,et al.  Low prevalence of methicillin-resistant Staphylococcus aureus (MRSA) at hospital admission in the Netherlands: the value of search and destroy and restrictive antibiotic use. , 2004, The Journal of hospital infection.

[19]  G. Duckworth Controlling methicillin resistant Staphylococcus aureus , 2003, BMJ : British Medical Journal.

[20]  Carlene A. Muto,et al.  SHEA Guideline for Preventing Nosocomial Transmission of Multidrug-Resistant Strains of Staphylococcus aureus and Enterococcus , 2003, Infection Control & Hospital Epidemiology.

[21]  Erkki Eerola,et al.  Elimination of Epidemic Methicillin-Resistant Staphylococcus aureus from a University Hospital and District Institutions, Finland , 2003, Emerging infectious diseases.

[22]  S. Cosgrove,et al.  Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  T. Karchmer,et al.  Cost-effectiveness of active surveillance cultures and contact/droplet precautions for control of methicillin-resistant Staphylococcus aureus. , 2002, The Journal of hospital infection.

[24]  D. Goldmann,et al.  Control of multiply resistant cocci: do international comparisons help? , 2001, The Lancet. Infectious diseases.

[25]  A. Simor,et al.  The Economic Impact of Methicillin-Resistant Staphylococcus aureus in Canadian Hospitals , 2001, Infection Control & Hospital Epidemiology.

[26]  Krinko Empfehlung zur Prävention und Kontrolle von Methicillinresistenten Staphylococcus aureus-Stämmen (MRSA) in Krankenhäusern und anderen medizinischen Einrichtungen , 1999 .

[27]  C. Brun-Buisson,et al.  Control of endemic methicillin-resistant Staphylococcus aureus: a cost-benefit analysis in an intensive care unit. , 1999, JAMA.